SCHEMBL2202072

SCHEMBL2202072

COCCN1CCN(C(=O)c2nn(C)c(-c3cccc(-c4cc5ccccc5o4)c3)c2C)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.46
DRD3 P35462 3/20 0.46
ALDH1A1 P00352 3/20 0.46
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
PKM P14618 1/20 0.41
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HRH4 Q9H3N8 1/20 0.38
MKNK1 Q9BUB5 5/20 0.38
MKNK2 Q9HBH9 3/20 0.38
EIF4E P06730 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2201254 0.91 ALDH1A1 (0.41) DRD2DRD3ALDH1A1RAB9AKDM4E
SCHEMBL2201671 0.89 DRD3 (0.39) DRD2DRD3ALDH1A1RAB9AKDM4E
SCHEMBL2202074 0.88 ALDH1A1 (0.47) DRD2DRD3ALDH1A1RAB9ANPC1
SCHEMBL2200710 0.88 GRIN2B (0.43) DRD2DRD3ALDH1A1KDM4EMEN1
SCHEMBL2197341 0.79 MKNK1 (0.51) ALDH1A1RAB9ANPC1KDM4EMEN1
SCHEMBL2199009 0.79 GRM5 (0.46) ALDH1A1RAB9ANPC1KDM4EMEN1
SCHEMBL2203141 0.79 MAPT (0.48) ALDH1A1RAB9ANPC1KDM4EMEN1
SCHEMBL2201258 0.78 ALDH1A1 (0.42) DRD2DRD3ALDH1A1RAB9AKDM4E
SCHEMBL2230472 0.78 POLR1A (0.41) ALDH1A1RAB9ANPC1PKMHPGD
SCHEMBL2201674 0.77 DRD3 (0.40) DRD2DRD3ALDH1A1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
EP-2182953-A2 NEW PYRAZOL DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-05-12 EP disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
WO-2009013211-A2 NEW PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 WO disclosed
WO-2009013211-A2 NEW PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 DRD2 1088/4885DRD3 751/4885ALDH1A1 1476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.